Shanghai Fuhong Ruilin Biotechnology

Shanghai Fuhong Ruilin Biotechnology is a subsidiary of Shanghai Henlius Biotech, a leading biopharmaceutical company based in China. The company is dedicated to the research and clinical development of innovative monoclonal antibodies, with a strong focus on oncology. It leverages the extensive R&D and manufacturing infrastructure of its parent company to advance its pipeline candidates. Key assets include HLX07, a humanized anti-EGFR monoclonal antibody, and HLX20, an anti-PD-L1 antibody. These programs are currently being evaluated in clinical trials for various solid tumors, including head and neck squamous cell carcinoma and colorectal cancer. Fuhong Ruilin serves as a strategic development arm within the Henlius ecosystem to accelerate the delivery of high-quality biologics to patients.